On Wednesday, Hologic reported quarter-four financial statements that topped the experts’ prediction. The firm announced $1.35B revenue and $2.07 EPS on expectations of $1.12 billion revenue and $1.23 earnings per share.
The US-based medical equipment venture is trading 41% high since the start of 2020, at $74.58, down from its 52-week high point. Hologic is performing better than the S&P 500, that is 6.58% from the beginning.
Meanwhile, Pfizer, which posted its financial reports on October 27, beat the analysts’ prediction. The firm reported Q3 earnings per share of $0.72 and revenue of $12.13 billion as compared to EPS of $0.71 and revenue of $12.31B.
Hologic added 1.13% in the after-hours market report.